FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Tuesday

 

Teva (Copaxone) denies CEO weighing an exit over board's meddling.

Teva (Copaxone) denies CEO weighing an exit over board's meddling

XXXIsrael is full of chatter about  and its latest round of cost-cutting plans. The Copaxone-Teva Pharmaceutical Industries rumor mill doesn't have to dig much for drama, what with workers striking, unions calling for executive pay cuts, and a former chairman calling for ditto. Not to mention high-level meetings among labor leaders, government officials and Teva's  current executive team.

The latest, according to an Israeli television report: CEO Jeremy Levin is considering making an exit. It's not the first such suggestion; during the company's second-quarter earnings call, Goldman Sachs analyst Jami Rubin wondered aloud about the board's support--or lack thereof--for Levin.

Apparently, Rubin anticipated some behind-the-scenes conflict, if Channel 2's report is any indication. According to the Israeli television news, the company's board of directors is far from united behind Levin's job-cutting drive, and management wrote the board to complain. "[T]he lack of unity among the board of directors and CEO hurts our ability to make the necessary changes," the letter stated, Channel 2 news reported (as quoted by Reuters).

What's more, the board has been meddling in Teva's daily affairs, the letter said, and that's hindering the company's efforts at a turnaround. The letter asked the board to back off, essentially--"reconsider its intervention in the daily course of business" was the actual phrase, as quoted by Reuters.

So, in the midst of the conflict, Levin's staff is telling Channel 2 that a. Chairman Philip Frost is trying to push Levin out, and b. Levin is considering resigning if the conflict with the board continues.

The company, however, says this is all baseless gossip. "All decisions made by the company's management, led by its CEO, have been made with consultation and agreement of the board," the company told the news service.

In the recent past, Frost has defended Levin against restive shareholders and critical analysts. Frost told Bloomberg that he was not only verbally supporting the company's management, but putting his money where his mouth is by buying shares. Is he still doing so? At this point, we don't know. But with the Israeli media all over Teva's current activities, we're sure to hear more soon.

Labels:



Go to Newer News Go to Older News